小剂量喹硫平联用舒必利对康复期精神分裂症维持治疗的效果

Effects of low-dose Quetiapine combined with Sulpiride on maintenance therapy of convalescent schizophrenia

目的:探究康复期精神分裂症患者行小剂量喹硫平联合舒必利治疗的临床效果及安全性。方法:选取72例康复期精神分裂症患者为研究对象,以患者入院时间先后顺序分为对照组36例和观察组36例。对照组单用小剂量喹硫平治疗,观察组行小剂量喹硫平联合舒必利治疗。通过阳性和阴性症状量表(PANSS)、简明精神病评定量表(BPRS)对两组患者治疗前后病情及症状改善情况进行评定,同时统计两组患者临床疗效及不良反应情况。结果:治疗前两组患者PANSS及BPRS评分差异差异无统计学意义(P>0.05);治疗后观察组患者PANSS及BPRS评分低于对照组,差异有统计学意义(P<0.05);观察组患者临床疗效94.44%,高于对照组的77.78%,差异有统计学意义(P<0.05);不良反应发生率为27.78%,低于对照组的30.55%,但差异无统计学意义(P>0.05)。结论:小剂量喹硫平联合舒必利治疗康复期精神分裂症临床效果优于单独使用小剂量喹硫平治疗,可有效改善患者的临床症状。

Objective: To investigate clinical efficacy and safety of low-dose Quetiapine combined with Sulpiride on patients with convalescent schizophrenia. Methods: 72 patients with convalescent schizophrenia were enrolled in the study. According to the admission time, these patients were divided into control group(36 cases) and observation group(36 cases). The control group received low-dose Quetiapine alone, while the observation group was given small-dose Quetiapine combined with Sulpiride. The positive and negative symptom scale(PANSS) and the brief psychiatric rating scale(BPRS) were used to evaluate the conditions of the two groups before and after the treatment as well as the improvements.Further, the clinical efficacies and adverse reactions of the two groups were statistically analyzed. Results: There were no significant differences in the PANSS and BPRS scores between the two groups before the treatment(P>0.05). The PANSS and BPRS scores of the observation group were lower than those of the control group after the treatment(P<0.05), and the differences were statistically significant(P<0.05). The clinical efficacy of the observation group was 94.44%, which was higher than that of the control group(77.78%), and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the observation group was 27.78%, which was lower than that of the control group(30.55%), but the difference was not statistically significant(P>0.05). Conclusions: Low-dose Quetiapine combined with Sulpiride in the treatment of convalescent schizophrenia is superior to single low-dose Quetiapine, and it can effectively improve the clinical symptoms of the patients.